Status:

RECRUITING

The Use of Melatonin for Delirium Prevention in Medically Hospitalized Patients

Lead Sponsor:

Sultan Qaboos University

Conditions:

Delirium

Eligibility:

All Genders

65+ years

Phase:

PHASE2

PHASE3

Brief Summary

The high prevalence of delirium in hospitalized older adults, with significant associated morbidity and mortality, emphasize the need for effective prevention strategies. Limited trials have explored ...

Detailed Description

Background and rationale: Delirium, a neuropsychiatric syndrome, manifests acutely with altered consciousness, cognitive impairment, and inattention, showing a fluctuating course.1 Delirium can prese...

Eligibility Criteria

Inclusion

  • Patient aged 65 years and above acutely admitted under the care of General Internal Medicine Unit

Exclusion

  • Patients admitted to the ward, however meeting requirement for vasopressors or non-invasive ventilation.
  • Patient admitted through emergency to Intensive Care Unit (ICU) or High Dependency Unit (HDU).
  • Aphasic patients.
  • Patients with language barriers.
  • Already taking melatonin or ramelteon at the time of randomization.
  • Presence of delirium at the time of randomization.
  • If enteral medications are contraindicated due to gastrointestinal conditions.
  • If enteral medications are not allowed due to unavailability of nasogastric tube
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (liver function tests) \> 3 times the upper limit of normal.
  • Patient on strong cytochrome P450 1A2 (CYP1A2) inhibitors (namely: fluvoxamine and viloxazine) .
  • Patient with active alcohol drinking or admitted with alcohol withdrawal syndrome.
  • Subject or proxy unable to provide informed consent within 24 hours of admission.
  • Patients with the following autoimmune diseases (Rheumatoid arthritis, inflammatory bowel disease and systemic lupus erythematosus).
  • Allergy to melatonin.

Key Trial Info

Start Date :

September 30 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2025

Estimated Enrollment :

240 Patients enrolled

Trial Details

Trial ID

NCT06509191

Start Date

September 30 2024

End Date

June 1 2025

Last Update

January 14 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Sultan Qaboos University Hospital

Muscat, Oman, 123

2

Sultan Qaboos University Hospital

Muscat, Oman, 123